18:48 , Apr 4, 2019 |  BC Extra  |  Company News

Cytovant launches with Asia focus, Medigene deal

Roivant and its Sinovant affiliate launched Cytovant, a new company that will seek to develop treatments for diseases prevalent in Asia. The newco also obtained a license in Asian territories to four T cell immunotherapy...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

DC Vaccine containing WT1/PRAME: Phase I/II started

Medigene began an open-label, Norwegian Phase I/II trial to evaluate its DC Vaccine containing WT1/PRAME for 50 weeks in about 20 AML patients who show complete remission after standard chemotherapy but are ineligible for stem...